Drug Discovery
By
Can Novartis’ 19 New Cardiovascular Studies at ESC 2025 Redefine the Future of Heart Disease Treatment?
Key Insights Leqvio: Can Inclisiran’s Expanding Role Become a Game-Changer in Cholesterol Management?Novartis is spotlighting the VICTORION-Difference study,…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty Medicine Leadership in 2025?
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Could Merck and Daiichi Sankyo’s 48% Response Rate with Ifinatamab Deruxtecan Redefine Treatment for Small Cell Lung Cancer?
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
